Skip to main content

Advertisement

Table 2 Randomised participants by website group

From: Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

Variable Website only Website with support No website Test
N = 45 N = 45 N = 45
Age (years), mean (SD) 45.76 (9.21) 45.13 (10.13) 42.18 (11.48) F(2,132) = 1.524, p = 0.222
Length of symptoms (years), mean (SD) 10.51 (8.19) 12.87 (9.47) 9.00 (8.14) KW, ap = 0.129
  Median (IQR) 10.00 (12.00) 12.00 (15.00) 7.50 (8.75)  
IBS-SSS total, mean (SD) 237.33 (85.36) 237.30 (100.78) 251.36 (75.92) F(2,132) = 0.377, p = 0.687
IBS-QOL score, mean (SD) 67.32 (17.89) 60.00 (3.13) 64.86 (19.39) F(2,132) = 1.65, p = 0.20
HADS score for anxiety, mean (SD) 8.73 (3.40) 9.46 (3.91) 10.00 (4.12) F(2,132) = 1.23, p = 0.30
HADS score for depression, mean (SD) 4.20 (2.87) 5.26 (3.68) 5.32 (3.56) KW, ap = 0.263
  Median (IQR) 4 (4) 5 (6) 5 (5)  
Deprivation score, mean (SD) 12.27 (9.07) 8.65 (5.54) 12.81 (9.40) KW, ap = 0.026*
  Median (IQR) 10.06 (9.79) 6.57 (7.63) 9.79 (9.21)  
Gender n (%)     
  Male 14 (46.7) 12 (40.0) 4 (13.3) X2(2) = 6.844, p = 0.034*
  Female 31(29.5) 34 (32.4) 40 (38.1)  
Type of IBS n (%)     X2(4) = 0.70, p = 0.953
  Constipation 5 (38.5) 5 (38.5) 3 (23.1)  
  Diarrhoea 14 (34.1) 13 (31.7) 14 (34.1)  
  Mixed 26 (32.1) 28 (34.6) 27 (33.3)  
Severity IBS on IBS SSS n (%)     
  Mild 10 (33.3) 12 (40.0) 8 (26.7) X2(4) = 1.37, p = 0.85
  Moderate 24 (32.4) 23 (31.1) 27 (36.5)  
  Severe 11 (35.5) 11 (35.5) 9 (29.0)  
Education n (%)     X2(10) = 3.65, p = 0.97
  No formal 2 (25.0) 4 (50.0) 2 (25.0)  
  GSCE/O 11 (31.4) 11 (31.4) 13 (37.1)  
  A level 11 (32.4) 10 (29.4) 13 (38.2)  
  Degree 12 (38.7) 10 (32.3) 9 (29.0)  
  Postgraduate 5 (33.3) 7 (46.7) 3 (20.0)  
  Other 4 (33.3) 4 (33.3) 4 (33.3)